{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:27:36Z","timestamp":1778693256590,"version":"3.51.4"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T00:00:00Z","timestamp":1519689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41380-018-0021-9","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T20:18:37Z","timestamp":1519762717000},"page":"364-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Are immunotherapies for Huntington\u2019s disease a realistic option?"],"prefix":"10.1038","volume":"24","author":[{"given":"H\u00e9l\u00e8na L.","family":"Denis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5919-1372","authenticated-orcid":false,"given":"Florian","family":"Lauruol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,27]]},"reference":[{"key":"21_CR1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/mp.2011.28","volume":"16","author":"D Soulet","year":"2011","unstructured":"Soulet D, Cicchetti F. The role of immunity in Huntington\u2019s disease. Mol Psychiatry. 2011;16:889\u2013902.","journal-title":"Mol Psychiatry"},{"key":"21_CR2","first-page":"nrdp20155","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, et al. Huntington disease. Nat Rev Dis Prim. 2015;1:10155.","journal-title":"Nat Rev Dis Prim"},{"key":"21_CR3","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.it.2015.04.007","volume":"36","author":"A Crotti","year":"2015","unstructured":"Crotti A, Glass CK. The choreography of neuroinflammation in Huntington\u2019s disease. Trends Immunol. 2015;36:364\u201373.","journal-title":"Trends Immunol"},{"key":"21_CR4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hbm.21008","volume":"32","author":"M Politis","year":"2011","unstructured":"Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington\u2019s disease: a multimodal imaging study. Hum Brain Mapp. 2011;32:258\u201370.","journal-title":"Hum Brain Mapp"},{"key":"21_CR5","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","volume":"205","author":"M Bj\u00f6rkqvist","year":"2008","unstructured":"Bj\u00f6rkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease. J Exp Med. 2008;205:1869\u201377.","journal-title":"J Exp Med"},{"key":"21_CR6","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1021\/pr0700753","volume":"6","author":"A Dalrymple","year":"2007","unstructured":"Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Bj\u00f6rkqvist M, Peters\u00e9n A, et al. Proteomic profiling of plasma in Huntington\u2019s disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res. 2007;6:2833\u201340.","journal-title":"J Proteome Res"},{"key":"21_CR7","doi-asserted-by":"crossref","first-page":"RRN1231","DOI":"10.1371\/currents.RRN1231","volume":"3","author":"E Wild","year":"2011","unstructured":"Wild E, Magnusson A, Lahiri N, Krus U, Orth M, Tabrizi SJ, et al. Abnormal peripheral chemokine profile in Huntington\u2019s disease. PLoS Curr. 2011;3:RRN1231\u00a0","journal-title":"PLoS Curr"},{"key":"21_CR8","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","volume":"130","author":"YF Tai","year":"2007","unstructured":"Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Microglial activation in presymptomatic Huntington\u2019s disease gene carriers. Brain 2007;130:1759\u201366.","journal-title":"Brain J Neurol"},{"key":"21_CR9","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1172\/JCI64484","volume":"122","author":"W Kwan","year":"2012","unstructured":"Kwan W, Tr\u00e4ger U, Davalos D, Chou A, Bouchard J, Andre R, et al. Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Invest. 2012;122:4737\u201347.","journal-title":"J Clin Invest"},{"key":"21_CR10","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","volume":"8","author":"JMM Burg van der","year":"2009","unstructured":"van der Burg JMM, Bj\u00f6rkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington\u2019s disease. Lancet Neurol. 2009;8:765\u201374.","journal-title":"Lancet Neurol"},{"key":"21_CR11","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/brain\/awt355","volume":"137","author":"U Tr\u00e4ger","year":"2014","unstructured":"Tr\u00e4ger U, Andre R, Lahiri N, Magnusson-Lind A, Weiss A, Grueninger S, et al. HTT-lowering reverses Huntington\u2019s disease immune dysfunction caused by NF\u03baB pathway dysregulation. Brain. 2014;137:819\u201333.","journal-title":"Brain J Neurol"},{"key":"21_CR12","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.1093\/hmg\/ddv335","volume":"24","author":"AI Ramsingh","year":"2015","unstructured":"Ramsingh AI, Manley K, Rong Y, Reilly A, Messer A. Transcriptional dysregulation of inflammatory\/immune pathways after active vaccination against Huntington\u2032s disease. Hum Mol Genet. 2015;24:6186\u201397.","journal-title":"Hum Mol Genet"},{"key":"21_CR13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1523\/JNEUROSCI.4846-11.2012","volume":"32","author":"W Kwan","year":"2012","unstructured":"Kwan W, Magnusson A, Chou A, Adame A, Carson MJ, Kohsaka S, et al. Bone marrow transplantation confers modest benefits in Mouse models of Huntington\u2019s disease. J Neurosci. 2012;32:133\u201342.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"21_CR14","first-page":"1582","volume":"65","author":"Huntington Study Group TREND-HD Investigators.","year":"2008","unstructured":"Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol. 2008;65:1582\u20139.","journal-title":"Arch Neurol"},{"key":"21_CR15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0278-5846(03)00021-6","volume":"27","author":"MA Hickey","year":"2003","unstructured":"Hickey MA, Chesselet M-F. Apoptosis in Huntington\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:255\u201365.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"21_CR16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1006\/exnr.1999.7170","volume":"159","author":"SK Singhrao","year":"1999","unstructured":"Singhrao SK, Neal JW, Morgan BP, Gasque P. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington\u2019s disease. Exp Neurol. 1999;159:362\u201376.","journal-title":"Exp Neurol"},{"key":"21_CR17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nn884","volume":"5","author":"AV Panov","year":"2002","unstructured":"Panov AV, Gutekunst C-A, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, et al. Early mitochondrial calcium defects in Huntington\u2019s disease are a direct effect of polyglutamines. Nat Neurosci. 2002;5:731\u20136.","journal-title":"Nat Neurosci"},{"key":"21_CR18","doi-asserted-by":"crossref","first-page":"8755","DOI":"10.1074\/jbc.R100062200","volume":"277","author":"DB Jump","year":"2002","unstructured":"Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem. 2002;277:8755\u20138.","journal-title":"J Biol Chem"},{"key":"21_CR19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.brainresbull.2006.10.020","volume":"72","author":"H Murck","year":"2007","unstructured":"Murck H, Manku M. Ethyl-EPA in Huntington disease: potentially relevant mechanism of action. Brain Res Bull. 2007;72:159\u201364.","journal-title":"Brain Res Bull"},{"key":"21_CR20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.intimp.2006.10.001","volume":"7","author":"DO Moon","year":"2007","unstructured":"Moon D-O, Kim K-C, Jin C-Y, Han M-H, Park C, Lee K-J, et al. Inhibitory effects of eicosapentaenoic acid on lipopolysaccharide-induced activation in BV2 microglia. Int Immunopharmacol. 2007;7:222\u20139.","journal-title":"Int Immunopharmacol"},{"key":"21_CR21","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1471-4159.2007.04848.x","volume":"103","author":"AM Minogue","year":"2007","unstructured":"Minogue AM, Lynch AM, Loane DJ, Herron CE, Lynch MA. Modulation of amyloid-beta-induced and age-associated changes in rat hippocampus by eicosapentaenoic acid. J Neurochem. 2007;103:914\u201326.","journal-title":"J Neurochem"},{"key":"21_CR22","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1006\/jsre.1998.5524","volume":"82","author":"CJ Lo","year":"1999","unstructured":"Lo CJ, Chiu KC, Fu M, Lo R, Helton S. Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NF kappa B activity. J Surg Res. 1999;82:216\u201321.","journal-title":"J Surg Res"},{"key":"21_CR23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/07315724.2004.10719345","volume":"23","author":"Y Zhao","year":"2004","unstructured":"Zhao Y, Joshi-Barve S, Barve S, Chen LH. Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. J Am Coll Nutr. 2004;23:71\u20138.","journal-title":"J Am Coll Nutr"},{"key":"21_CR24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0306-4522(01)00409-2","volume":"109","author":"JJ Clifford","year":"2002","unstructured":"Clifford JJ, Drago J, Natoli AL, Wong JYF, Kinsella A, Waddington JL, et al. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington\u2019s disease. Neuroscience. 2002;109:81\u20138.","journal-title":"Neuroscience"},{"key":"21_CR25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.expneurol.2005.07.021","volume":"196","author":"JM Raamsdonk Van","year":"2005","unstructured":"Van Raamsdonk JM, Pearson J, Rogers DA, Lu G, Barakauskas VE, Barr AM, et al. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol. 2005;196:266\u201372.","journal-title":"Exp Neurol"},{"key":"21_CR26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00001756-200201210-00011","volume":"13","author":"KS Vaddadi","year":"2002","unstructured":"Vaddadi KS, Soosai E, Chiu E, Dingjan P. A randomised, placebo-controlled, double blind study of treatment of Huntington\u2019s disease with unsaturated fatty acids. Neuroreport. 2002;13:29\u201333.","journal-title":"Neuroreport"},{"key":"21_CR27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00001756-200201210-00029","volume":"13","author":"BK Puri","year":"2002","unstructured":"Puri BK, Bydder GM, Counsell SJ, Corridan BJ, Richardson AJ, Hajnal JV, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport. 2002;13:123\u20136.","journal-title":"Neuroreport"},{"key":"21_CR28","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1177\/147323000803600505","volume":"36","author":"BK Puri","year":"2008","unstructured":"Puri BK, Bydder GM, Manku MS, Clarke A, Waldman AD, Beckmann CF. Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington\u2019s disease. J Int Med Res. 2008;36:896\u2013905.","journal-title":"J Int Med Res"},{"key":"21_CR29","unstructured":"M.E. Cudkowicz, M. McDermott, R. Doolan, F. Marshall, K. Kieburtz, HSG. \u200bA phase 2 trial of minocycline in Huntington\u2019s disease. Mov Disord. 2009;24:S1\u2013653."},{"key":"21_CR30","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/mds.23236","volume":"25","author":"Huntington Study Group DOMINO Investigators.","year":"2010","unstructured":"Huntington Study Group DOMINO Investigators. A futility study of minocycline in Huntington\u2019s disease. Mov Disord. 2010;25:2219\u201324.","journal-title":"Mov Disord"},{"key":"21_CR31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1212\/01.WNL.0000133403.30559.FF","volume":"63","author":"Huntington Study Group.","year":"2004","unstructured":"Huntington Study Group. Minocycline safety and tolerability in Huntington disease. Neurology. 2004;63:547\u20139.","journal-title":"Neurology"},{"key":"21_CR32","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/mds.20018","volume":"19","author":"M Thomas","year":"2004","unstructured":"Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington\u2019s disease: a pilot study. Mov Disord. 2004;19:692\u20135.","journal-title":"Mov Disord"},{"key":"21_CR33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/77528","volume":"6","author":"M Chen","year":"2000","unstructured":"Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000;6:797\u2013801.","journal-title":"Nat Med"},{"key":"21_CR34","doi-asserted-by":"crossref","first-page":"10483","DOI":"10.1073\/pnas.1832501100","volume":"100","author":"X Wang","year":"2003","unstructured":"Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, et al. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington\u2019s disease. Proc Natl Acad Sci USA. 2003;100:10483\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"21_CR35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbadis.2005.11.002","volume":"1762","author":"EC Stack","year":"2006","unstructured":"Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW, et al. Combination therapy using minocycline and coenzyme Q10 in R6\/2 transgenic Huntington\u2019s disease mice. Biochim Biophys Acta. 2006;1762:373\u201380.","journal-title":"Biochim Biophys Acta"},{"key":"21_CR36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/417074a","volume":"417","author":"S Zhu","year":"2002","unstructured":"Zhu S, Stavrovskaya IG, Drozda M, Kim BYS, Ona V, Li M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002;417:74\u20138.","journal-title":"Nature"},{"key":"21_CR37","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1523\/JNEUROSCI.22-05-01763.2002","volume":"22","author":"DC Wu","year":"2002","unstructured":"Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci. 2002;22:1763\u201371.","journal-title":"J Neurosci"},{"key":"21_CR38","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ana.10818","volume":"54","author":"E Diguet","year":"2003","unstructured":"Diguet E, Rouland R, Tison F. Minocycline is not beneficial in a phenotypic mouse model of Huntington\u2019s disease. Ann Neurol. 2003;54:841\u20132.","journal-title":"Ann Neurol"},{"key":"21_CR39","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1111\/j.0953-816X.2004.03372.x","volume":"19","author":"E Diguet","year":"2004","unstructured":"Diguet E, Fernagut P-O, Wei X, Du Y, Rouland R, Gross C, et al. Deleterious effects of minocycline in animal models of Parkinson\u2019s disease and Huntington\u2019s disease. Eur J Neurosci. 2004;19:3266\u201376.","journal-title":"Eur J Neurosci"},{"key":"21_CR40","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.10614","volume":"54","author":"DL Smith","year":"2003","unstructured":"Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PAS, et al. Minocycline and doxycycline are not beneficial in a model of Huntington\u2019s disease. Ann Neurol. 2003;54:186\u201396.","journal-title":"Ann Neurol"},{"key":"21_CR41","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.nbd.2004.09.017","volume":"18","author":"K Bantubungi","year":"2005","unstructured":"Bantubungi K, Jacquard C, Greco A, Pintor A, Chtarto A, Tai K, et al. Minocycline in phenotypic models of Huntington\u2019s disease. Neurobiol Dis. 2005;18:206\u201317.","journal-title":"Neurobiol Dis"},{"key":"21_CR42","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1093\/hmg\/ddl210","volume":"15","author":"DE Ehrnhoefer","year":"2006","unstructured":"Ehrnhoefer DE, Duennwald M, Markovic P, Wacker JL, Engemann S, Roark M, et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington\u2019s disease models. Hum Mol Genet. 2006;15:2743\u201351.","journal-title":"Hum Mol Genet"},{"key":"21_CR43","first-page":"394","volume":"43","author":"C Santangelo","year":"2007","unstructured":"Santangelo C, Var\u00ec R, Scazzocchio B, Di Benedetto R, Filesi C, Masella R. Polyphenols, intracellular signalling and inflammation. Ann Ist Super Sanita. 2007;43:394\u2013405.","journal-title":"Ann Ist Super Sanita"},{"key":"21_CR44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00394-011-0216-1","volume":"51","author":"B Relja","year":"2012","unstructured":"Relja B, T\u00f6ttel E, Breig L, Henrich D, Schneider H, Marzi I, et al. Plant polyphenols attenuate hepatic injury after hemorrhage\/resuscitation by inhibition of apoptosis, oxidative stress, and inflammation via NF-kappaB in rats. Eur J Nutr. 2012;51:311\u201321.","journal-title":"Eur J Nutr"},{"key":"21_CR45","doi-asserted-by":"crossref","first-page":"e11951","DOI":"10.1371\/journal.pone.0011951","volume":"5","author":"KS Kang","year":"2010","unstructured":"Kang KS, Wen Y, Yamabe N, Fukui M, Bishop SC, Zhu BT. Dual beneficial effects of (-)-epigallocatechin-3-gallate on levodopa methylation and hippocampal neurodegeneration: in vitro and in vivo studies. PLoS ONE. 2010;5:e11951.","journal-title":"PLoS ONE"},{"key":"21_CR46","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s11064-006-9166-z","volume":"31","author":"Z Xu","year":"2006","unstructured":"Xu Z, Chen S, Li X, Luo G, Li L, Le W. Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis. Neurochem Res. 2006;31:1263\u20139.","journal-title":"Neurochem Res"},{"key":"21_CR47","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/jnr.20315","volume":"78","author":"R Li","year":"2004","unstructured":"Li R, Huang Y-G, Fang D, Le W-D. (-)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury. J Neurosci Res. 2004;78:723\u201331.","journal-title":"J Neurosci Res"},{"key":"21_CR48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejphar.2015.11.048","volume":"770","author":"J Cheng-Chung Wei","year":"2016","unstructured":"Cheng-Chung Wei J, Huang H-C, Chen W-J, Huang C-N, Peng C-H, Lin C-L. Epigallocatechin gallate attenuates amyloid \u03b2-induced inflammation and neurotoxicity in EOC 13.31 microglia. Eur J Pharmacol. 2016;770:16\u201324.","journal-title":"Eur J Pharmacol"},{"key":"21_CR49","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.4103\/1673-5374.165502","volume":"10","author":"P Boadas-Vaello","year":"2015","unstructured":"Boadas-Vaello P, Verd\u00fa E. Epigallocatechin-3-gallate treatment to promote neuroprotection and functional recovery after nervous system injury. Neural Regen Res. 2015;10:1390\u20132.","journal-title":"Neural Regen Res"},{"key":"21_CR50","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1248\/bpb.27.1353","volume":"27","author":"D Ichikawa","year":"2004","unstructured":"Ichikawa D, Matsui A, Imai M, Sonoda Y, Kasahara T. Effect of various catechins on the IL-12p40 production by murine peritoneal macrophages and a macrophage cell line, J774.1. Biol Pharm Bull. 2004;27:1353\u20138.","journal-title":"Biol Pharm Bull"},{"key":"21_CR51","doi-asserted-by":"crossref","first-page":"3805S","DOI":"10.1093\/jn\/133.11.3805S","volume":"133","author":"JK Kundu","year":"2003","unstructured":"Kundu JK, Na H-K, Chun K-S, Kim Y-K, Lee SJ, Lee SS, et al. Inhibition of phorbol ester-induced COX-2 expression by epigallocatechin gallate in mouse skin and cultured human mammary epithelial cells. J Nutr. 2003;133:3805S\u20133810S.","journal-title":"J Nutr"},{"key":"21_CR52","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/hmg\/ddu456","volume":"24","author":"M Gratuze","year":"2015","unstructured":"Gratuze M, No\u00ebl A, Julien C, Cisbani G, Milot-Rousseau P, Morin F, et al. Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington\u2019s disease. Hum Mol Genet. 2015;24:86\u201399.","journal-title":"Hum Mol Genet"},{"key":"21_CR53","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/brain\/awv107","volume":"138","author":"R Vuono","year":"2015","unstructured":"Vuono R, Winder-Rhodes S, de Silva R, Cisbani G, Drouin-Ouellet J, REGISTRY Investigators of the European Huntington\u2019s Disease Network. et al. The role of tau in the pathological process and clinical expression of Huntington\u2019s disease. Brain. 2015;138:1907\u201318.","journal-title":"Brain J Neurol"},{"key":"21_CR54","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/brain\/awx255","volume":"140","author":"G Cisbani","year":"2017","unstructured":"Cisbani G, Maxan A, Kordower JH, Planel E, Freeman TB, Cicchetti F. Presence of tau pathology within fetal neural allografts in patients with Huntington\u2019s and Parkinson\u2019s disease. Brain. 2017;140:2982\u201392.","journal-title":"Brain J Neurol"},{"key":"21_CR55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.febslet.2014.11.026","volume":"589","author":"HJ Wobst","year":"2015","unstructured":"Wobst HJ, Sharma A, Diamond MI, Wanker EE, Bieschke J. The green tea polyphenol (\u2212)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios. FEBS Lett. 2015;589:77\u201383.","journal-title":"FEBS Lett"},{"key":"21_CR56","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","volume":"263","author":"JL L\u00f3pez-Send\u00f3n Moreno","year":"2016","unstructured":"L\u00f3pez-Send\u00f3n Moreno JL, Garc\u00eda Caldentey J, Trigo Cubillo P, Ruiz Romero C, Garc\u00eda Ribas G, Alonso Arias MAA, et al. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease. J Neurol. 2016;263:1390\u2013400.","journal-title":"J Neurol"},{"key":"21_CR57","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/cn200114w","volume":"3","author":"S Valdeolivas","year":"2012","unstructured":"Valdeolivas S, Satta V, Pertwee RG, Fern\u00e1ndez-Ruiz J, Sagredo O. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington\u2019s disease: role of CB1 and CB2 receptors. ACS Chem Neurosci. 2012;3:400\u20136.","journal-title":"ACS Chem Neurosci"},{"key":"21_CR58","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/mol.115.101980","volume":"89","author":"RB Laprairie","year":"2016","unstructured":"Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM. Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease. Mol Pharmacol. 2016;89:364\u201375.","journal-title":"Mol Pharmacol"},{"key":"21_CR59","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/cdd.2015.11","volume":"22","author":"C Bl\u00e1zquez","year":"2015","unstructured":"Bl\u00e1zquez C, Chiarlone A, Bellocchio L, Resel E, Pruunsild P, Garc\u00eda-Rinc\u00f3n D, et al. The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K\/Akt\/mTORC1\/BDNF pathway. Cell Death Differ. 2015;22:1618\u201329.","journal-title":"Cell Death Differ"},{"key":"21_CR60","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","volume":"293","author":"C Zuccato","year":"2001","unstructured":"Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease. Science. 2001;293:493\u20138.","journal-title":"Science"},{"key":"21_CR61","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neuroscience.2010.06.056","volume":"170","author":"MJ Dowie","year":"2010","unstructured":"Dowie MJ, Howard ML, Nicholson LFB, Faull RLM, Hannan AJ, Glass M. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington\u2019s disease transgenic mice. Neuroscience. 2010;170:324\u201336.","journal-title":"Neuroscience"},{"key":"21_CR62","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fnins.2016.00406","volume":"10","author":"G Navarro","year":"2016","unstructured":"Navarro G, Morales P, Rodr\u00edguez-Cueto C, Fern\u00e1ndez-Ruiz J, Jagerovic N, Franco R. Targeting cannabinoid CB2 receptors in the central nervous system. medicinal chemistry approaches with focus on neurodegenerative disorders. Front Neurosci. 2016;10:406\u00a0","journal-title":"Front Neurosci"},{"key":"21_CR63","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/glia.20838","volume":"57","author":"O Sagredo","year":"2009","unstructured":"Sagredo O, Gonz\u00e1lez S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington\u2019s disease. Glia. 2009;57:1154\u201367.","journal-title":"Glia"},{"key":"21_CR64","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jchemneu.2014.06.004","volume":"59\u201360","author":"MJ Dowie","year":"2014","unstructured":"Dowie MJ, Grimsey NL, Hoffman T, Faull RLM, Glass M. Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington\u2019s disease brain. J Chem Neuroanat. 2014;59\u201360:62\u201371.","journal-title":"J Chem Neuroanat"},{"key":"21_CR65","doi-asserted-by":"crossref","first-page":"18259","DOI":"10.1523\/JNEUROSCI.4008-12.2012","volume":"32","author":"J Bouchard","year":"2012","unstructured":"Bouchard J, Truong J, Bouchard K, Dunkelberger D, Desrayaud S, Moussaoui S, et al. Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington\u2019s disease. J Neurosci. 2012;32:18259\u201368.","journal-title":"J Neurosci"},{"key":"21_CR66","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ng1219","volume":"35","author":"C Zuccato","year":"2003","unstructured":"Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, et al. Huntingtin interacts with REST\/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet. 2003;35:76\u201383.","journal-title":"Nat Genet"},{"key":"21_CR67","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJMoa1104318","volume":"366","author":"G Comi","year":"2012","unstructured":"Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366:1000\u20139.","journal-title":"N Engl J Med"},{"key":"21_CR68","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jns.2011.02.019","volume":"306","author":"W Br\u00fcck","year":"2011","unstructured":"Br\u00fcck W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci. 2011;306:173\u20139.","journal-title":"J Neurol Sci"},{"key":"21_CR69","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1517\/17425255.2011.556618","volume":"7","author":"J Th\u00f6ne","year":"2011","unstructured":"Th\u00f6ne J, Gold R. Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Drug Metab Toxicol. 2011;7:365\u201370.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"21_CR70","doi-asserted-by":"crossref","first-page":"31652","DOI":"10.1038\/srep31652","volume":"6","author":"M Garcia-Miralles","year":"2016","unstructured":"Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, et al. Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Sci Rep. 2016;6:31652\u00a0","journal-title":"Sci Rep"},{"key":"21_CR71","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-04990-1","volume":"7","author":"G Ellrichmann","year":"2017","unstructured":"Ellrichmann G, Blusch A, Fatoba O, Brunner J, Hayardeny L, Hayden M, et al. Laquinimod treatment in the R6\/2 mouse model. Sci Rep. 2017;7:4947.","journal-title":"Sci Rep"},{"key":"21_CR72","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/jnc.13553","volume":"137","author":"L Dobson","year":"2016","unstructured":"Dobson L, Tr\u00e4ger U, Farmer R, Hayardeny L, Loupe P, Hayden MR, et al. Laquinimod dampens hyperactive cytokine production in Huntington\u2019s disease patient myeloid cells. J Neurochem. 2016;137:782\u201394.","journal-title":"J Neurochem"},{"key":"21_CR73","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.4049\/jimmunol.0903302","volume":"184","author":"T Okuno","year":"2010","unstructured":"Okuno T, Nakatsuji Y, Moriya M, Takamatsu H, Nojima S, Takegahara N, et al. Roles of Sema4D-plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. J Immunol. 2010;184:1499\u2013506.","journal-title":"J Immunol"},{"key":"21_CR74","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/hmg\/ddl013","volume":"15","author":"A Hodges","year":"2006","unstructured":"Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, et al. Regional and cellular gene expression changes in human Huntington\u2019s disease brain. Hum Mol Genet. 2006;15:965\u201377.","journal-title":"Hum Mol Genet"},{"key":"21_CR75","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.nbd.2014.10.008","volume":"73","author":"ES Smith","year":"2015","unstructured":"Smith ES, Jonason A, Reilly C, Veeraraghavan J, Fisher T, Doherty M, et al. SEMA4D compromises blood\u2013brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiol Dis. 2015;73:254\u201368.","journal-title":"Neurobiol Dis"},{"key":"21_CR76","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nbd.2015.01.002","volume":"76","author":"AL Southwell","year":"2015","unstructured":"Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiol Dis. 2015;76:46\u201356.","journal-title":"Neurobiol Dis"},{"key":"21_CR77","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1007\/s11481-012-9399-3","volume":"7","author":"AG Granja","year":"2012","unstructured":"Granja AG, Carrillo-Salinas F, Pagani A, G\u00f3mez-Ca\u00f1as M, Negri R, Navarrete C, et al. A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. J NeuroImmune Pharmacol. 2012;7:1002\u201316.","journal-title":"J NeuroImmune Pharmacol"},{"key":"21_CR78","doi-asserted-by":"crossref","first-page":"e94733","DOI":"10.1371\/journal.pone.0094733","volume":"9","author":"FJ Carrillo-Salinas","year":"2014","unstructured":"Carrillo-Salinas FJ, Navarrete C, Mecha M, Feli\u00fa A, Collado JA, Cantarero I, et al. A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis. PLoS ONE. 2014;9:e94733.","journal-title":"PLoS ONE"},{"key":"21_CR79","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.4003","volume":"22","author":"AS Dickey","year":"2016","unstructured":"Dickey AS, Pineda VV, Tsunemi T, Liu PP, Miranda HC, Gilmore-Hall SK, et al. PPAR-\u03b4 is repressed in Huntington\u2019s disease, is required for normal neuronal function and can be targeted therapeutically. Nat Med. 2016;22:37\u201345.","journal-title":"Nat Med"},{"key":"21_CR80","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.freeradbiomed.2016.06.023","volume":"100","author":"JC Corona","year":"2016","unstructured":"Corona JC, Duchen MR. PPAR\u03b3 as a therapeutic target to rescue mitochondrial function in neurological disease. Free Radic Biol Med. 2016;100:153\u201363.","journal-title":"Free Radic Biol Med"},{"key":"21_CR81","doi-asserted-by":"crossref","DOI":"10.1038\/srep29789","volume":"6","author":"J D\u00edaz-Alonso","year":"2016","unstructured":"D\u00edaz-Alonso J, Para\u00edso-Luna J, Navarrete C, Del R\u00edo C, Cantarero I, Palomares B, et al. VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington\u2019s disease. Sci Rep. 2016;6:29789.","journal-title":"Sci Rep"},{"key":"21_CR82","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1084\/jem.189.5.865","volume":"189","author":"M Kerschensteiner","year":"1999","unstructured":"Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WEF, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med. 1999;189:865\u201370.","journal-title":"J Exp Med"},{"key":"21_CR83","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jneuroim.2006.09.001","volume":"182","author":"N Kruse","year":"2007","unstructured":"Kruse N, Cetin S, Chan A, Gold R, L\u00fchder F. Differential expression of BDNF mRNA splice variants in mouse brain and immune cells. J Neuroimmunol. 2007;182:13\u201321.","journal-title":"J Neuroimmunol"},{"key":"21_CR84","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12974-017-0930-6","volume":"14","author":"D Xu","year":"2017","unstructured":"Xu D, Lian D, Wu J, Liu Y, Zhu M, Sun J, et al. Brain-derived neurotrophic factor reduces inflammation and hippocampal apoptosis in experimental Streptococcus pneumoniae meningitis. J Neuroinflamm. 2017;14:156\u00a0","journal-title":"J Neuroinflamm"},{"key":"21_CR85","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1172\/JCI41356","volume":"120","author":"SM Massa","year":"2010","unstructured":"Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest. 2010;120:1774\u201385.","journal-title":"J Clin Invest"},{"key":"21_CR86","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd4024","volume":"12","author":"FM Longo","year":"2013","unstructured":"Longo FM, Massa SM. Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease. Nat Rev Drug Discov. 2013;12:507\u201325.","journal-title":"Nat Rev Drug Discov"},{"key":"21_CR87","doi-asserted-by":"crossref","first-page":"18712","DOI":"10.1523\/JNEUROSCI.1310-13.2013","volume":"33","author":"DA Simmons","year":"2013","unstructured":"Simmons DA, Belichenko NP, Yang T, Condon C, Monbureau M, Shamloo M, et al. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6\/2 and BACHD mouse models of Huntington\u2019s disease. J Neurosci. 2013;33:18712\u201327.","journal-title":"J Neurosci"},{"key":"21_CR88","doi-asserted-by":"crossref","first-page":"e96544","DOI":"10.1371\/journal.pone.0096544","volume":"9","author":"LT Alto","year":"2014","unstructured":"Alto LT, Chen X, Ruhn KA, Trevi\u00f1o I, Tansey MG. AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington\u2019s disease. PLoS ONE. 2014;9:e96544.","journal-title":"PLoS ONE"},{"key":"21_CR89","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1093\/hmg\/ddu151","volume":"23","author":"HY Hsiao","year":"2014","unstructured":"Hsiao H-Y, Chiu F-L, Chen C-M, Wu Y-R, Chen H-M, Chen Y-C, et al. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington\u2019s disease. Hum Mol Genet. 2014;23:4328\u201344.","journal-title":"Hum Mol Genet"},{"key":"21_CR90","doi-asserted-by":"crossref","first-page":"32312","DOI":"10.1074\/jbc.273.48.32312","volume":"273","author":"R Newton","year":"1998","unstructured":"Newton R, Seybold J, Kuitert LME, Bergmann M, Barnes PJ. Repression of cyclooxygenase-2 and prostaglandin E2release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. J Biol Chem. 1998;273:32312\u201321.","journal-title":"J Biol Chem"},{"key":"21_CR91","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1073\/pnas.97.2.657","volume":"97","author":"MI Diamond","year":"2000","unstructured":"Diamond MI, Robinson MR, Yamamoto KR. Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor. Proc Natl Acad Sci. 2000;97:657\u201361.","journal-title":"Proc Natl Acad Sci"},{"key":"21_CR92","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1093\/hmg\/ddt667","volume":"23","author":"M Maheshwari","year":"2014","unstructured":"Maheshwari M, Bhutani S, Das A, Mukherjee R, Sharma A, Kino Y, et al. Dexamethasone induces heat shock response and slows down disease progression in mouse and fly models of Huntington\u2019s disease. Hum Mol Genet. 2014;23:2737\u201351.","journal-title":"Hum Mol Genet"},{"key":"21_CR93","doi-asserted-by":"crossref","first-page":"e37929","DOI":"10.1371\/journal.pone.0037929","volume":"7","author":"SM Chafekar","year":"2012","unstructured":"Chafekar SM, Duennwald ML. Impaired heat shock response in cells expressing full-length polyglutamine-expanded huntingtin. PLoS ONE. 2012;7:e37929.","journal-title":"PLoS ONE"},{"key":"21_CR94","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1749-6632.1998.tb08327.x","volume":"856","author":"PL Moseley","year":"1998","unstructured":"Moseley PL. Heat shock proteins and the inflammatory response. Ann N Y Acad Sci. 1998;856:206\u201313.","journal-title":"Ann N Y Acad Sci"},{"key":"21_CR95","first-page":"225","volume":"61","author":"A Nuti","year":"1991","unstructured":"Nuti A, Maremmani C, Ceravolo R, Pavese N, Bonuccelli U, Muratorio A. [Dexamethasone therapy in Huntington chorea: preliminary results]. Riv Neurol. 1991;61:225\u20137.","journal-title":"Riv Neurol"},{"key":"21_CR96","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/mt.2013.132","volume":"21","author":"SM Ellison","year":"2013","unstructured":"Ellison SM, Trabalza A, Tisato V, Pazarentzos E, Lee S, Papadaki V, et al. Dose-dependent neuroprotection of VEGF165 in Huntington\u2019s disease striatum. Mol Ther. 2013;21:1862\u201375.","journal-title":"Mol Ther"},{"key":"21_CR97","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1093\/hmg\/11.19.2233","volume":"11","author":"E Fossale","year":"2002","unstructured":"Fossale E, Wheeler VC, Vrbanac V, Lebel L-A, Teed A, Mysore JS, et al. Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice. Hum Mol Genet. 2002;11:2233\u201341.","journal-title":"Hum Mol Genet"},{"key":"21_CR98","doi-asserted-by":"crossref","first-page":"18167","DOI":"10.1074\/jbc.M109.018325","volume":"284","author":"A Carnemolla","year":"2009","unstructured":"Carnemolla A, Fossale E, Agostoni E, Michelazzi S, Calligaris R, De Maso L, et al. Rrs1 is involved in endoplasmic reticulum stress response in Huntington disease. J Biol Chem. 2009;284:18167\u201373.","journal-title":"J Biol Chem"},{"key":"21_CR99","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.bcp.2015.07.032","volume":"97","author":"J Egea","year":"2015","unstructured":"Egea J, Buendia I, Parada E, Navarro E, Le\u00f3n R, Lopez MG. Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection. Biochem Pharmacol. 2015;97:463\u201372.","journal-title":"Biochem Pharmacol"},{"key":"21_CR100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.expneurol.2004.01.006","volume":"187","author":"JK Ryu","year":"2004","unstructured":"Ryu JK, Kim SU, McLarnon JG. Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington\u2019s disease. Exp Neurol. 2004;187:150\u20139.","journal-title":"Exp Neurol"},{"key":"21_CR101","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.neuroscience.2006.05.043","volume":"141","author":"JK Ryu","year":"2006","unstructured":"Ryu JK, Choi HB, McLarnon JG. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington\u2019s disease. Neuroscience. 2006;141:1835\u201348.","journal-title":"Neuroscience"},{"key":"21_CR102","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000","volume":"20","author":"RJ Ferrante","year":"2000","unstructured":"Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington\u2019s disease. J Neurosci. 2000;20:4389\u201397.","journal-title":"J Neurosci"},{"key":"21_CR103","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ana.10476","volume":"53","author":"W Zhang","year":"2003","unstructured":"Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol. 2003;53:267\u201370.","journal-title":"Ann Neurol"},{"key":"21_CR104","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1525-0016(03)00063-7","volume":"7","author":"TW Miller","year":"2003","unstructured":"Miller TW, Shirley TL, Wolfgang WJ, Kang X, Messer A. DNA vaccination against mutant huntingtin ameliorates the HDR6\/2 diabetic phenotype. Mol Ther. 2003;7:572\u20139.","journal-title":"Mol Ther"},{"key":"21_CR105","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.csbj.2016.07.003","volume":"14","author":"ALJ Marschall","year":"2016","unstructured":"Marschall ALJ, D\u00fcbel S. Antibodies inside of a cell can change its outside: can intrabodies provide a new therapeutic paradigm? Comput Struct Biotechnol J. 2016;14:304\u20138.","journal-title":"Comput Struct Biotechnol J"},{"key":"21_CR106","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1073\/pnas.022631799","volume":"99","author":"A Khoshnan","year":"2002","unstructured":"Khoshnan A, Ko J, Patterson PH. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc Natl Acad Sci USA. 2002;99:1002\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"21_CR107","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1073\/pnas.071058398","volume":"98","author":"JM Lecerf","year":"2001","unstructured":"Lecerf J-M, Shirley TL, Zhu Q, Kazantsev A, Amersdorfer P, Housman DE, et al. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington\u2019s disease. Proc Natl Acad Sci USA. 2001;98:4764\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"21_CR108","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/NEN.0b013e3181f530ec","volume":"69","author":"A Snyder-Keller","year":"2010","unstructured":"Snyder-Keller A, McLear JA, Hathorn T, Messer A. Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6\/1 mice. J Neuropathol Exp Neurol. 2010;69:1078\u201385.","journal-title":"J Neuropathol Exp Neurol"},{"key":"21_CR109","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","volume":"29","author":"AL Southwell","year":"2009","unstructured":"Southwell AL, Ko J, Patterson PH. Intrabody gene therapy ameliorates motor, cognitive and neuropathological symptoms in multiple mouse models of Huntington\u2019s disease. J Neurosci. 2009;29:13589.","journal-title":"J Neurosci"},{"key":"21_CR110","volume":"6","author":"J Zha","year":"2016","unstructured":"Zha J, Liu X-M, Zhu J, Liu S-Y, Lu S, Xu P-X, et al. A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses. Sci Rep. 2016;6:36631.","journal-title":"Sci Rep"},{"key":"21_CR111","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s13311-013-0193-6","volume":"10","author":"A Messer","year":"2013","unstructured":"Messer A, Joshi SN. Intrabodies as neuroprotective therapeutics. Neurotherapeutics.2013;10:447\u201358.","journal-title":"Neurotherapeutics."},{"key":"21_CR112","doi-asserted-by":"crossref","first-page":"e29199","DOI":"10.1371\/journal.pone.0029199","volume":"6","author":"DC Butler","year":"2011","unstructured":"Butler DC, Messer A. Bifunctional anti-Huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant Huntingtin exon 1 protein fragments. PLoS ONE. 2011;6:e29199.","journal-title":"PLoS ONE"},{"key":"21_CR113","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1474-4422(15)00177-5","volume":"14","author":"JB Carroll","year":"2015","unstructured":"Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ. Treating the whole body in Huntington\u2019s disease. Lancet Neurol. 2015;14:1135\u201342.","journal-title":"Lancet Neurol"},{"key":"21_CR114","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00401-016-1582-9","volume":"132","author":"I Jeon","year":"2016","unstructured":"Jeon I, Cicchetti F, Cisbani G, Lee S, Li E, Bae J, et al. Human-to-mouse prion-like propagation of mutant Huntingtin protein. Acta Neuropathol (Berl). 2016;132:577\u201392.","journal-title":"Acta Neuropathol (Berl)"},{"key":"21_CR115","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","volume":"19","author":"CA Gutekunst","year":"1999","unstructured":"Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, et al. Nuclear and neuropil aggregates in Huntington\u2019s disease: relationship to neuropathology. J Neurosci. 1999;19:2522\u201334.","journal-title":"J Neurosci"},{"key":"21_CR116","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jasms.2007.04.012","volume":"18","author":"X Liu","year":"2007","unstructured":"Liu X, Valentine SJ, Plasencia MD, Trimpin S, Naylor S, Clemmer DE. Mapping the human plasma proteome by SCX-LC-IMS-MS. J Am Soc Mass Spectrom. 2007;18:1249\u201364.","journal-title":"J Am Soc Mass Spectrom"},{"key":"21_CR117","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller JRC, et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients. J Clin Invest. 2015;125:1979\u201386.","journal-title":"J Clin Invest"},{"key":"21_CR118","unstructured":"Bartl S, Southwell AL, Parth M, Salhat N, Burkert M, Siddu A, et al. Antibody-based targeting of mutant Huntingtin for the treatment of Huntington\u2019s disease. Abstract, 12th Annual Huntington's Disease Therapeutics Conference, CHDI Foundation April 2017."},{"key":"21_CR119","unstructured":"OW Smrzka, Southwell AL, Bartl S, Parth M, Burkert M, Villanueva EB, et al. Passive treatment with huntingtin (HTT)-specific mAb\u2019s lowers HTT levels and improves motor performance in YAC128 mice. Abstract,\u00a011th\u00a0Annual Huntington's Disease Therapeutics Conference, CHDI Foundation February 2017."},{"key":"21_CR120","first-page":"151","volume":"11","author":"BS Main","year":"2017","unstructured":"Main BS, Minter MR. Microbial immuno-communication in neurodegenerative diseases. Front Neurosci. 2017;11:151","journal-title":"Front Neurosci"},{"key":"21_CR121","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/acn3.214","volume":"2","author":"HD Rosas","year":"2015","unstructured":"Rosas HD, Doros G, Bhasin S, Thomas B, Gevorkian S, Malarick K, et al. A systems-level \u201cmisunderstanding\u201d: the plasma metabolome in Huntington\u2019s disease. Ann Clin Transl Neurol. 2015;2:756\u201368.","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41380-018-0021-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41380-018-0021-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41380-018-0021-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T20:57:34Z","timestamp":1684616254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-018-0021-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,27]]},"references-count":121,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["21"],"URL":"https:\/\/doi.org\/10.1038\/s41380-018-0021-9","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,27]]},"assertion":[{"value":"4 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}